A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer

For colorectal cancer with peritoneal metastasis, the current first-line standard treatment offers very limited benefits and short survival. Therefore, it is necessary to seek new treatment strategies to improve the prognosis and survival of such patients. Based on previous basic research and early clinical research results, the strategy of PIPAC combined with MMC or RTX provides a feasible solution that can benefit patients with advanced colorectal cancer and peritoneal metastasis undergoing first-line treatment. This study aims to evaluate the effectiveness of PIPAC combined with MMC or RTX

Trial Details

NCT ID
NCT07349043
Phase
PHASE1
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Mitomycin-PIPAC
  • Raltitrexed-PIPAC
Locations (sample)
  • Hangzhou, Other (Non U.s.), China|30.29365,120.16142

Key Eligibility Criteria

  • Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites.
  • No gender limitation, aged 18 to 75 years old;
  • ECOG score ≤2;
  • Subjects without other malignant diseases;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →